초록 ▼

The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one

The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.

대표청구항 ▼

1. A method of treating cancer in a human individual, comprising injecting into the individual an effective amount of a pharmaceutical composition comprising paclitaxel and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises albumin, wherein the albumin a

1. A method of treating cancer in a human individual, comprising injecting into the individual an effective amount of a pharmaceutical composition comprising paclitaxel and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises albumin, wherein the albumin and the paclitaxel in the composition are formulated as particles, wherein the particles in the composition have a particle size of less than about 200 nm, and wherein the weight ratio of albumin to paclitaxel in the composition is about 1:1 to about 9:1, wherein the cancer is ovarian cancer. 2. The method of claim 1, wherein the albumin is human serum albumin. 3. The method of claim 1, wherein the ratio (w/w) of the albumin to the paclitaxel in the pharmaceutical composition is 1:1 to 9:1. 4. The method of claim 1, wherein the ratio (w/w) of the albumin to the paclitaxel in the pharmaceutical composition is about 9:1. 5. The method of claim 1, wherein the pharmaceutical composition is injected intravenously. 6. The method of claim 3, wherein the pharmaceutical composition is injected intravenously. 7. The method of claim 4, wherein the pharmaceutical composition is injected intravenously. 8. A method of treating cancer in a human individual, comprising injecting into the individual an effective amount of a pharmaceutical composition comprising paclitaxel and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises albumin, wherein the albumin and the paclitaxel in the composition are formulated as particles, wherein the particles in the composition have a particle size of less than about 200 nm, and wherein the weight ratio of albumin to paclitaxel in the composition is about 1:1 to about 9:1, wherein the cancer is prostate cancer. 9. The method of claim 8, wherein the albumin is human serum albumin. 10. The method of claim 8, wherein the ratio (w/w) of the albumin to the paclitaxel in the pharmaceutical composition is 1:1 to 9:1. 11. The method of claim 8, wherein the ratio (w/w) of the albumin to the paclitaxel in the pharmaceutical composition is about 9:1. 12. The method of claim 8, wherein the pharmaceutical composition is injected intravenously. 13. The method of claim 10, wherein the pharmaceutical composition is injected intravenously. 14. The method of claim 11, wherein the pharmaceutical composition is injected intravenously. 15. A method of treating cancer in a human individual, comprising injecting into the individual an effective amount of a pharmaceutical composition comprising paclitaxel and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises albumin, wherein the albumin and the paclitaxel in the composition are formulated as particles, wherein the particles in the composition have a particle size of less than about 200 nm, and wherein the weight ratio of albumin to paclitaxel in the composition is about 1:1 to about 9:1, wherein the cancer is head and neck cancer. 16. The method of claim 15, wherein the albumin is human serum albumin. 17. The method of claim 15, wherein the ratio (w/w) of the albumin to the paclitaxel in the pharmaceutical composition is 1:1 to 9:1. 18. The method of claim 15, wherein the ratio (w/w) of the albumin to the paclitaxel in the pharmaceutical composition is about 9:1. 19. The method of claim 15, wherein the pharmaceutical composition is injected intravenously. 20. The method of claim 17, wherein the pharmaceutical composition is injected intravenously. 21. The method of claim 18, wherein the pharmaceutical composition is injected intravenously.